Allergan plans to introduce prescription eyelash enhancer
On its front page, the
(1/14, A1, Singer) reports that, at the end of this month, Allergan "plans to introduce Latisse (bimatoprost), the first federally approved prescription drug for growing longer, lusher lashes." Latisse "has the same formula as Allergan's eye drops for glaucoma, called Lumigan (bimatoprost ophthalmic)," which is a prostaglandin analog "meant to reduce dangerous pressure in the eyeball." One of bimatoprost's side effects is "to make the eyelashes of many patients longer and fuller." Now, "some medical experts say they worry that cosmetic customers may occasionally experience some of the glaucoma drug's other side effects, which can include red, itchy eyes and changes in eyelid pigmentation." Meanwhile, "some financial analysts...wonder how many people will want to spend $120 for a monthly dose of lash-lengthening Latisse." Nevertheless, "Allergan plans to introduce Latisse this month primarily to cosmetic doctors like dermatologists, but declined to discuss marketing plans."
No comments:
Post a Comment